BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leru PM, Anton VF, Ureche C, Zurac S, Bratu O, Neagoe CD. Mast cell activation syndromes - evaluation of current diagnostic criteria and laboratory tools in clinical practice (Review). Exp Ther Med 2020;20:2348-51. [PMID: 32765713 DOI: 10.3892/etm.2020.8947] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Halili A. Temporal model for central sensitization: A hypothesis for mechanism and treatment using Systemic Manual Therapy, a focused review. MethodsX 2022. [DOI: 10.1016/j.mex.2022.101942] [Reference Citation Analysis]
2 Kim K, Kim J, Park SG. A fully human anti-c-Kit monoclonal antibody 2G4 inhibits proliferation and degranulation of human mast cells. Mol Cell Biochem. [DOI: 10.1007/s11010-022-04557-3] [Reference Citation Analysis]
3 Leru PM. Evaluation and Classification of Mast Cell Disorders: A Difficult to Manage Pathology in Clinical Practice. Cureus 2022;14:e22177. [PMID: 35174041 DOI: 10.7759/cureus.22177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Boldeanu E, Avram M, Rezmeriţă L. Mast cell activation syndrome — clinical presentation and diagnostic criteria. Alergologia 2021;1:7. [DOI: 10.26416/aler.5.1.2021.4445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Boda D. 2nd Special Issue: Tackling key immunological and immuno-dermatological pathways and their link to treatment options. Exp Ther Med 2020;20:2339-43. [PMID: 32793306 DOI: 10.3892/etm.2020.8977] [Reference Citation Analysis]